Cogent Biosciences Inc
COGTHealthcare|Biotechnology|USA
$38.87
-1.62 (-4.00%)
Tangible Book
$3.18
Earnings Power
$4.21
Upcoming Data Readouts (3)
Mar 2027
Est. completion
P1P2Intrahepatic Cholangiocarcinoma (Icc)
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316n=110
May 2028
Est. completion
P1Advanced Solid Tumor, Adult
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562n=100
Jul 2029
Est. completion
P1PIK3CA Mutations
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506n=90
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Jun 2026
P2
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
NCT06208748May 2025
P2
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
NCT05186753